10-Q: Seer Inc. Reports Q1 2025 Financial Results: Revenue Up 37% Despite Continued Net Losses

Seer Inc. reports a 37% increase in revenue for Q1 2025 compared to Q1 2024, driven by higher product sales and service revenue, while still experiencing a net loss.

Summary

• Seer Inc. reported its financial results for the first quarter of 2025.
• Revenue increased by 37% to $4.205 million, compared to $3.066 million in Q1 2024, driven by higher product and service revenue.
• Product revenue increased by 73% to $2.890 million.
• Service revenue increased by 195% to $1.203 million.
• The company experienced a net loss of $19.948 million, slightly lower than the $20.679 million loss in Q1 2024.
• Research and development expenses decreased by 7% to $11.350 million.
• Selling, general and administrative expenses decreased by 20% to $11.442 million.
• The company's cash, cash equivalents, and investments totaled $285.3 million as of March 31, 2025.
• The company believes its current cash resources are sufficient to fund operations for at least the next twelve months.
• The company repurchased 352,000 shares of Class A common stock at an average price of $1.91 per share under its share repurchase program.
• As of March 31, 2025, the company has $12.6 million available for additional share repurchases under the current authorization.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue growth is positive, the continued net losses and reliance on future market acceptance temper the overall outlook. The company's strong cash position provides some reassurance.

Positives

• Revenue increased by 37% year-over-year, indicating growing market traction.
• Product and service revenue both experienced substantial growth.
• The net loss decreased slightly compared to the same period last year.
• The company maintains a strong cash position, providing a financial runway for at least the next twelve months.
• The company is actively managing its capital structure through share repurchases.

Negatives

• The company continues to operate at a net loss.
• The company has an accumulated deficit of $412.3 million.
• The company expects to continue to incur significant losses and does not expect positive cash flows from operations for the foreseeable future.
• Total other income decreased by $3.6 million, or 80%, compared to the three months ended March 31, 2024. The decrease was mainly due to the loss in the equity method investment and lower rates of interest earned on cash invested in money market funds, U.S. Treasury securities, and commercial paper.

Risks

• The company's future success depends on the broad market acceptance of the Proteograph Product Suite.
• The company relies on a single contract manufacturer for its instruments.
• The company faces intense competition in the life sciences technology market.
• The company's operating results may fluctuate significantly in the future.
• The company's business depends significantly on research and development spending by academic and other research institutions, and other third parties, including commercial organizations, and any reduction in spending could limit demand for our products and adversely affect our business, results of operations, financial condition and prospects.

Future Outlook

The company expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. The Company believes that its cash and cash equivalents and investments as of March 31, 2025 provide sufficient capital resources to continue its operations for at least twelve months from the issuance date of the accompanying unaudited condensed consolidated financial statements.

Management Comments

• Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth.
• The Company believes that its cash and cash equivalents and investments as of March 31, 2025 provide sufficient capital resources to continue its operations for at least twelve months from the issuance date of the accompanying unaudited condensed consolidated financial statements.

Industry Context

Seer operates in the competitive life sciences technology market, facing competition from established players and emerging companies in the proteomics and genomics fields. The company's performance is influenced by trends in research and development spending, government funding, and the adoption of new technologies in the scientific community.

Comparison to Industry Standards

• Comparing Seer's growth rate to companies like Quanterix, which also focuses on proteomics, provides context.
• Quanterix has demonstrated significant revenue growth in recent years, setting a benchmark for the industry.
• Thermo Fisher Scientific and Danaher, larger players in the life sciences sector, serve as benchmarks for operational efficiency and market reach.
• Seer's ability to expand its customer base and increase utilization of its Proteograph system will be critical in achieving industry-standard performance.
• The company's investment in PrognomiQ is similar to strategic investments made by other life science companies to expand their market reach and technology portfolio.

Legal Proceedings

• The Company is not currently a party to any material legal proceedings.

Related Party Transactions

• PrognomiQ constitutes a related party and, as of March 31, 2025 and December 31, 2024, the Company recorded $ 52.2 thousand and $ 0.4 million in related party receivables, respectively, on the condensed consolidated balance sheets mainly due from product sales and services revenue.
• For the three months ended March 31, 2025 and 2024, the Company recognized revenue of $ 51.9 thousand and $ 1.0 million, respectively, of which $ 5.4 thousand and $ 0.8 million were from product sales.
• On August 12, 2024, the Company entered into a preferred stock purchase agreement with PrognomiQ, pursuant to which the Company purchased $ 10.0 million of PrognomiQ's Series D Preferred Stock.

Stakeholder Impact

• Shareholders: The share repurchase program and revenue growth could positively impact shareholder value, but continued losses remain a concern.
• Employees: The company's ability to attract and retain qualified personnel is crucial for future success.
• Customers: The company's focus on improving the Proteograph Product Suite and expanding its applications will benefit customers.
• Suppliers: Maintaining strong relationships with suppliers is essential for ensuring a stable supply chain.
• Creditors: The company's strong cash position provides reassurance to creditors.

Next Steps

• Continue to broadly commercialize the Proteograph Product Suite.
• Attract, hire and retain qualified personnel.
• Continue to build our sales, marketing, service, support and distribution infrastructure as part of our commercialization efforts.
• Build-out and expand our in-house NP manufacturing capabilities.
• Continue to engage in research and development of other products and enhancements to the Proteograph Product Suite.
• Implement operational, financial and management information systems.
• Obtain, maintain, expand, and protect our intellectual property portfolio.
• Build the infrastructure to operate and scale as a public company.

Key Dates

Keywords

Seer, Proteograph, Revenue, Net Loss, Financial Results, Q1 2025, Proteomics, Share Repurchase, Investments, Cash